Cadrenal Therapeutics, Inc. (CVKD) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Cadrenal Therapeutics, Inc.'s filing signal continuing negative.

Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions. Its lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor targeting heparin-induced thrombocytopenia (HIT), a severe immune-mediated thrombotic disorder. The company also has two other clinical-stage assets in its pipeline: tecarfarin, an oral vitamin K antagonist designed for patients with complex needs like kidney dysfunction or left ventricular assist devices, and frunexian, an intravenous Factor XIa inhibitor for acute care settings. Cadrenal is advancing CAD-1005 through Phase 3 trials following an End-of-Phase 2 meeting with the FDA, and is also evaluating tecarfarin for specific patient populations and frunexian for acute care indications.

Revenue is expected to be driven by the successful development and commercialization of its product candidates, primarily CAD-1005, tecarfarin, and frunexian, following regulatory approvals.